A recent study found that overexpression of IL-1β reduced Aβ-related pathology by modulating innate immune responses or promoting nonamyloidogenic APP cleavage in mouse and cell culture models of AD, suggesting that IL-1β may play a beneficial role in limiting AD pathology [22, 23]. This evidence concerns the gene APP and Alzheimer disease.